Price control, ad-hoc regulatory changes and new policies may hamper pharma sector growth: Pfizer

摘要

Leading pharma firm, Pfizer, fears that the pharma industry is expected to face challenges from price controls, ad-hoc regulatory changes and new policies that may impact sustainable growth. "Even though economic outlook is expected to remain positive, there are several headwinds in the healthcare and pharmaceutical regulatory space," the company had said in its annual note to shareholders.